FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease
- 2 August 2013
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 44 (6) , 693-703
Abstract
Recent studies have shown that chronic endothelial dysfunction can impair multiple aspects of renal physiology and, in turn, contribute to renal fibrosis. Sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. The aim of our study was to investigate the effect of FTY720, an S1P analog, on the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. Thirty male Sprague–Dawley rats were used in this study. Seven days after surgery, we placed the animals into three groups: sham surgery; 5/6 nephrectomized (Nx) rats; and 5/6Nx + FTY720 (1 mg/kg/day). All of the animals were sacrificed 12 weeks after surgery. We obtained and analyzed blood and kidney tissue samples from all of the groups. Glomerular capillary density and peritubular capillary (PTC) density were determined by CD31 immunostaining. The expression of transforming growth factor beta 1 (TGF-β1), collagen IV, fibronectin, endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) were analyzed by immunohistochemistry, reverse transcription-polymerase chain reaction and western blotting. The 5/6Nx group exhibited increased blood urea nitrogen and serum creatinine, visible renal histological changes, pro-fibrotic molecule (TGF-β1) and production of extracellular matrix proteins such as collagen IV and fibronectin and decreased glomerular and PTC density, compared to the sham controls (P < 0.01). We observed that treatment with FTY720 reduced these abnormalities. Furthermore, the level of NO, the expression levels of eNOS and VEGF were downregulated in the kidney tissue in 5/6Nx rats, FTY720 treatment significantly attenuated this decrease. FTY720 prevents the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.Keywords
This publication has 45 references indexed in Scilit:
- FTY720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1P1/3 in Diabetic Heart DiseasePLOS ONE, 2012
- Progression of renal fibrosis: the underestimated role of endothelial alterationsFibrogenesis & Tissue Repair, 2012
- Nitric oxide synthase derangements and hypertension in kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2012
- Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Role of sphingolipids in murine radiation‐induced lung injury: protection by sphingosine 1‐phosphate analogsThe FASEB Journal, 2011
- Prevention of Diabetes by FTY720-Mediated Stabilization of Peri-Islet Tertiary Lymphoid OrgansDiabetes, 2010
- Regulation of vascular permeability by sphingosine 1-phosphateMicrovascular Research, 2009
- Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptorCellular Signalling, 2007
- Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high‐density lipoproteinsBritish Journal of Pharmacology, 2007